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ime Dependence of Defibrillator Benefit
fter Coronary Revascularization in the Multicenter
utomatic Defibrillator Implantation Trial (MADIT)-II
lan Goldenberg, MD,* Arthur J. Moss, MD,* Scott McNitt, MS,* Wojciech Zareba, MD, PHD,*
. Jackson Hall, PHD,† Mark L. Andrews, BBS,* David J. Wilber, MD,‡ Helmut U. Klein, MD,§
or the MADIT-II Investigators
ochester, New York; Maywood, Illinois; and Magdeburg, Germany
OBJECTIVES The study was designed to assess the effect of elapsed time from coronary revascularization
(CR) on the benefit of the implantable cardioverter-defibrillator (ICD) and the risk of sudden
cardiac death (SCD) in patients with ischemic left ventricular dysfunction.
BACKGROUND The ICD improves survival in appropriately selected high-risk cardiac patients by 30% to
54%. However, in the Coronary Artery Bypass Graft (CABG)-Patch trial no evidence of
improved survival was shown among a similar population of patients in whom an ICD was
implanted prophylactically at the time of elective CABG.
METHODS The outcome by time from CR was analyzed in 951 patients in whom a revascularization
procedure was performed before enrollment in the Multicenter Automatic Defibrillator
Implantation Trial (MADIT)-II.
RESULTS The adjusted hazard ratio (HR) of ICD versus conventional therapy was 0.64 (p  0.01)
among patients enrolled more than six months after CR, whereas no survival benefit with
ICD therapy was shown among patients enrolled six months or earlier after CR (HR 1.19;
p  0.76). In the conventional therapy group, the risk of cardiac death increased significantly
with increasing time from CR (p for trend  0.009), corresponding mainly to a six-fold
increase in the risk of SCD among patients enrolled more than six months after CR.
CONCLUSIONS In patients with ischemic left ventricular dysfunction, the efficacy of ICD therapy after CR
is time dependent, with a significant life-saving benefit in patients receiving device
implantation more than six months after CR. The lack of ICD benefit when implanted early
after CR may be related to a relatively low risk of SCD during this time period. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.048Cardiol 2006;47:1811–7) © 2006 by the American College of Cardiology Foundation
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sudden cardiac death (SCD) constitutes about one-quarter
f all coronary heart disease (CHD)-related major events
nd more than half of all CHD-related deaths. Ventricular
rrhythmia is believed to be the most common direct cause
1). Coronary heart disease patients with left ventricular
See page 1818
ysfunction have been shown to be at high risk for SCD,
nd in this population the implantable cardioverter-
efibrillator (ICD) has been demonstrated to reduce mor-
ality by 30% to 54% (2–6) and the risk of SCD by 67% (7).
he Coronary Artery Bypass Graft (CABG)-Patch trial,
owever, failed to show a benefit from ICD therapy in a
imilar population of high-risk cardiac patients who were
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005, accepted December 13, 2005.ndergoing CABG surgery (8). The lack of ICD benefit in
his study may be related to the proximity of device
mplantation to the coronary revascularization (CR) proce-
ure, compared with other primary prevention ICD trials
2–5).
The present study was performed to evaluate the effect of
lapsed time from CR on ICD benefit and the risk of SCD
n high-risk CHD patients enrolled in the Multicenter
utomatic Defibrillator Implantation Trial (MADIT)-II.
ETHODS
he design and results of the MADIT-II study have been
eported elsewhere (3). Briefly, 1,232 patients with docu-
ented prior myocardial infarction and a left ventricular
jection fraction of 30% were randomized to receive a
rophylactic ICD or conventional medical therapy in a 3:2
atio. Screened patients were excluded from enrollment if
hey had class IV congestive heart failure, CR within the
revious three months, elapsed interval from most recent
yocardial infarction of 1 month, or advanced medical
omorbidity. After a mean follow-up of 20 months, the
tudy was terminated by the Data Safety and Monitoring
oard. Unadjusted mortality was 19.8% in the conventional
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Defibrillator Efficacy and Revascularization May 2, 2006:1811–7herapy group and 14.2% in the ICD group, and the overall
azard ratio (HR) was 0.69 (95% confidence interval [CI]
.51 to 0.93).
Nine hundred fifty-one patients who had CABG and/or
ercutaneous coronary intervention (PCI) before enroll-
ent were included in the current analysis (time from last
R: mean 64.44  58.22 months, median 48.89 months,
nterquartile range 82.50 months); 580 of the patients who
ad undergone CR were allocated to the ICD group, and
71 were allocated to the conventional therapy group. In 12
atients CR was performed three months or less before
nrollment owing to authorized protocol deviations. Time-
ependence of mortality and ICD benefit was examined by
ividing times from most recent CR procedure to enroll-
ent into an early post-CR period (6 months or less); an
ntermediate post-CR period (6 to 60 months); and a late
Table 1. Baseline Characteristics by Time From
Characteristic, n (%)
<6 Mont
(n  130
Age 65 yrs 70 (54
Female gender 18 (14
NYHA functional class 2† 84 (66
Angina functional class 2† 92 (73
Hypertension 79 (61
Diabetes mellitus 30 (23
Arial fibrillation 35 (27
CR type‡
CABG 59 (45
PCI 72 (55
1 CR procedure 60 (14
BUN 9 mmol/l (25 mg/dl) 29 (23
Left bundle branch block 15 (12
QRS duration 0.12 34 (26
EF 25% 38 (29
Allocation to the ICD group 70 (54
Medical therapy
ACE inhibitors or ARB 103 (79
Digitalis 65 (50
Beta-blockers 93 (72
Amiodarone 13 (10
Lipid-lowering agents§ 83 (64
*p  0.05 for the comparison among the three post-corona
(NYHA) and angina functional class represent the highest c
bypass graft (CABG) or percutaneous coronary intervention
1 CR procedures were considered when either or both
enrollment. §Statins comprised 95% of lipid-lowering agent
Abbreviations and Acronyms
CABG  coronary artery bypass graft
CHD  coronary heart disease
CR  coronary revascularization
ICD  implantable cardioverter-defibrillator
MADIT  Multicenter Automatic Defibrillator
Implantation Trial
PCI  percutaneous coronary intervention
SCD  sudden cardiac deathACE  angiotensin-converting enzyme; ARB  angiotensin-re
fraction; ICD  implantable cardioverter-defibrillator.ost CR period (more than 60 months). Those time frames
ere chosen based upon current knowledge of the natural
istory of coronary artery disease progression after CR
9,10). Accordingly, during the early period there is little
rogression in graft disease (9), and the process of restenosis
fter coronary stenting is usually complete, with little
rogression thereafter (10); during the intermediate period
ew stenoses develop in graft conduits and/or native vessels,
ut most (80%) of the post-CABG patients are free from
ngina (9); and during the late period there is accelerated
raft stenosis and/or degeneration and progression of native
oronary artery disease (9).
A modified Hinkle-Thaler system was used to classify
eaths, as described previously (7).
tatistical analysis. Baseline characteristics of the patients
ithin the post-CR subgroups were compared and con-
rasted using the chi-square test and Fisher exact test, as
ppropriate. Significant variables affecting outcome were
ncorporated into a Cox proportional-hazards regression
odel to determine covariate-adjusted hazard ratios for: 1)
CD benefit by time from CR; and 2) the mode of death by
ime from CR in conventionally treated patients. Kaplan-
eier estimates of all-cause mortality by treatment group,
tratified according to time from CR, were estimated and
raphically displayed according to the method of Kaplan
nd Meier, with comparison of cumulative events by the
Time From CR
7–60 Months
(n  414)
>60 Months
(n  407)
193 (47) 250 (61)*
78 (19) 32 (8)*
252 (62) 258 (64)
290 (71) 292 (72)
222 (54) 200 (49)
152 (37) 146 (36)*
112 (27) 130 (32)
219 (53) 265 (65)*
195 (47) 142 (35)*
211 (48) 171 (39)
120 (29) 129 (32)
64 (17) 81 (22)*
137 (33) 183 (45)*
196 (47) 206 (51)*
247 (60) 263 (65)
312 (75) 318 (78)
244 (59) 230 (57)
269 (65) 239 (59)*
26 (6) 37 (9)
302 (73) 282 (69)
ascularization (CR) groups. †New York Heart Association
ring the three months before enrollment. ‡Coronary artery
were defined as the last CR procedure prior to enrollment;
ures were performed more than once in a patient beforeCR
hs
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May 2, 2006:1811–7 Defibrillator Efficacy and Revascularizationog-rank test. Analyses were performed with the use of SAS
oftware (version 9.13, SAS Institute, Cary, North Caro-
ina), and a two-sided probability value of 0.05 was used
or declaring statistical significance.
ESULTS
f the 951 patients who underwent CR, 130 patients had
he procedure 6 months before enrollment in the study
early: mean  SD 4  1 months, median 4 months,
nterquartile range 3 to 5 months), 414 patients within 6 to
0 months (intermediate: mean  SD 30  16 months,
edian 27 months, interquartile range 15 to 44 months),
nd 404 patients 60 months (late: mean  SD 119  48
onths, median 107 months, interquartile range 81 to 147
onths). Seventy-four percent of the patients who under-
ent CR had CABG at any time in their past, 57% had
CI, and both procedures were performed in 31% of
atients. Baseline characteristics of study patients in the
ost-CR subgroups are shown in Table 1. Compared with
he early and intermediate post-CR subgroups, the late
ost-CR subgroup had a higher proportion of older patients
65 years), a lower frequency of female patients, and a
igher proportion of patients who had CABG as their last
R procedure before enrollment. The proportion of pa-
ients with diabetes mellitus, a low ejection fraction
25%), and electrocardiographic abnormalities, including
eft bundle branch block and a QRS duration of 0.12 s,
ncreased with increasing time after CR, whereas medical
herapy with beta-blockers was administered less frequently
ith increasing time after CR. There were no significant
ifferences between the conventional and ICD treatment
roups with regard to baseline clinical characteristics within
he post-CR subgroups (data not shown).
efibrillator efficacy by elapsed time from coronary
evascularization. Among patients enrolled during the
arly post-CR period, the two-year Kaplan-Meier estimates
f all-cause mortality in the ICD and conventional therapy
roups were similar (Fig. 1A); whereas among patients
nrolled after the early post-CR period, all-cause mortality
ates were lower in the ICD group than in the conventional
herapy group (Figs. 1B and 1C).
In multivariate analysis (Table 2), ICD therapy was
ssociated with an overall 30% reduction in the risk of
ll-cause mortality (p  0.01). There was a significant 36%
eduction in the risk of all-cause mortality among patients
ho had CR 6 months before enrollment, corresponding
o a significant 45% and a marginally significant 33%
eduction in the risk of all-cause mortality among patients
nrolled during the intermediate and late post-CR periods,
espectively. No survival benefit with ICD therapy was
hown among patients in whom the device was implanted
uring the early post-CR period. The benefit of ICD
herapy after the early post-CR period was consistent when
arrower post-CR time intervals were analyzed (Fig. 2). WDefibrillator therapy was associated with an overall sig-
ificant 63% reduction in the risk of SCD (p  0.001).
igure 1. Kaplan-Meier estimates of probability of all-cause mortality by
reatment group among patients enrolled (A) 6 months after coronary
evascularization (CR), (B) 7 to 60 months after coronary revascularization,
nd (C) 60 months after coronary revascularization. ICD  implantable
ardioverter-defibrillator.hen analyzed by elapsed time from CR, treatment with an
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Defibrillator Efficacy and Revascularization May 2, 2006:1811–7CD was associated with a significant reduction in the risk
f SCD in each CR period6 months before enrollment (7
o 60 months: 73% reduction; p 0.004;60 months: 60%
eduction; p  0.03; corresponding to a 66% reduction in
he risk of SCD among patients enrolled during the overall
6 months post-CR period; p  0.001). Defibrillator
herapy did not reduce SCD risk in patients enrolled during
he early post-CR period, and a trend to an interaction
etween the 6 months and 6 months post-CR periods
as observed when the efficacy of ICD for reducing SCD
isk was analyzed (p value for treatment-time interaction 
.16). Kaplan-Meier estimates of the cumulative probability
f SCD 1 and 2 years after enrollment demonstrated very
ow, and similar, SCD rates in the ICD and conventional
herapy groups among patients in whom CR was performed
6 months before enrollment (Fig. 3A). The rate of SCD
as increased in patients in whom CR was performed after
his time period in the two treatment groups; and one- and
wo-year rates of SCD were significantly lower in the ICD
Table 2. Multivariate Analysis: ICD Efficacy by
All-Cause
HR (95% CI)
Total population (n  1,232) 0.70 (0.53–0.92
Time from CR
6 months (n  130) 1.19 (0.40–3.54
6 months (n  821) 0.64 (0.45–0.90
7–60 months (n  414) 0.55 (0.31–0.97
60 months (n  407) 0.67 (0.43–1.03
Adjusted for age65 years, ejection fraction25%, and treat
†p value for interaction  0.16.
CI  confidence interval; CR  coronary revasculari
defibrillator.igure 2. Two-year Kaplan-Meier estimates of all-cause mortality in the two
onventional (conv); open bars  implantable cardioverter-defibrillator (ICD).roup than in the conventional therapy group in patients
ho enrolled in the intermediate (Fig. 3B) and late (Fig.
C) post-CR periods.
Although subgroup analysis of CABG surgery or PCI
as associated with too few events to carry out a separate
ox analysis, Kaplan-Meier estimates of the cumulative rate
f all-cause mortality and SCD at two years among patients
ho had CABG as an isolated procedure, PCI as an isolated
rocedure, or multiple revascularization procedures before
nrollment demonstrated consistent results. Each therapeu-
ic modality was associated with similar survival rates in the
CD and conventional therapy groups among patients in
hom the procedure was performed 6 months before
nrollment and with improved survival in ICD-allocated
atients in whom the procedure was performed 6 months
efore enrollment (Table 3).
nalysis of mortality events in the conventional group. Mor-
ality rates in conventionally treated patients increased as a
unction of time from the most recent CR to enrollment
sed Time From CR
tality Sudden Cardiac Death
p Value HR (95% CI) p Value
0.01 0.37 (0.23–0.58) 0.001
0.76* 2.01 (0.18–22.22) 0.57†
0.01* 0.34 (0.19–0.61) 0.001†
0.04 0.27 (0.11–0.66) 0.004
0.07 0.40 (0.19–0.86) 0.02
ith beta-blockers at baseline. *p value for interaction 0.29.
HR  hazard ratio; ICD  implantable cardioverter-Elap
Mor
)
)
)
)
)
ment wtreatment groups by time from coronary revascularization. Solid bars 
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May 2, 2006:1811–7 Defibrillator Efficacy and Revascularizationunadjusted all-cause mortality rates: 10%, 15%, and 25% in
he respective early, intermediate, and late post-CR sub-
igure 3. Kaplan-Meier estimates of probability of sudden cardiac death by
reatment group among patients enrolled (A) 6 months after coronary
evascularization (CR), (B) 7 to 60 months after coronary revascularization,
nd (C) 60 months after coronary revascularization. ICD  implantable
ardioverter-defibrillator.roups; p 0.01). Cox regression analysis (Table 4) showed rsignificant increase in the risk of all-cause mortality and
ardiac death with increasing time from CR (p for trend 
.01 and 0.009, respectively). The increase in risk of cardiac
eath 6 months after CR was related mainly to a six-fold
ncrease in the risk of SCD among patients enrolled during
his time period as compared with patients enrolled 6
onths after CR (p for trend  0.07), whereas the risk of
on-SCD was not significantly different among the three
ost-CR subgroups (p for trend  0.56). Although the
umber of deaths was small, the proportion of sudden
ardiac deaths to total deaths was 17% among patients
nrolled during the early post-CR period and 60% among
atients enrolled after this time period (p  0.04) (Fig 4).
ISCUSSION
e have shown that in patients with ischemic left ventric-
lar dysfunction, the benefit of ICD therapy after CR is
ime dependent. There was a significant 36% and 68%
eduction in the risk of all-cause mortality and SCD,
espectively, in patients who had undergone CR more than
ix months before enrollment, whereas no such benefit was
emonstrated in patients enrolled within six months after
R. The change in ICD efficacy corresponded to a signif-
cant increase in the risk of cardiac death more than six
onths after CR in conventionally treated patients, attrib-
ted mainly to a six-fold increase in the risk of SCD,
hereas no change in the risk of non-SCD was observed
ith increasing time after CR. Thus, the lack of ICD
enefit when implanted early after CR may be related to the
elatively low risk of arrhythmic mortality during this time
eriod.
Myocardial ischemia has been suggested to be an impor-
ant trigger for development of ventricular tachyarrhythmias
11). Therefore, CR may attenuate subsequent SCD risk.
he Coronary Artery Surgery Study (12) and European
oronary Surgery Study (13) demonstrated reductions in
CD with surgical revascularization versus medical therapy
n a population of patients with normal, or mildly reduced,
eft ventricular function. A subsequent analysis of the
tudies of Left Ventricular Dysfunction trials (14) showed
hat in patients with an ejection fraction of 35%, prior
ABG was independently associated with a significant 25%
eduction in risk of death and a 46% reduction in risk of
CD. This study, however, did not analyze the effect of
lapsed time from CR on mortality risk. We have shown, in
similar population of patients with left ventricular dys-
unction, that risk reduction conferred by CR was confined
ainly to the early (six months or less) post-CR period.
Our findings are consistent with those of the CABG-
atch trial, in which no evidence of improved survival was
hown among patients with CHD, a depressed left ventric-
lar ejection fraction, and an abnormal signal-averaged
lectrocardiogram in whom an ICD was implanted prophy-
actically at the time of CABG (8). Notably, the hazard
atio for ICD benefit in the CABG-Patch trial (1.07; p 
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Defibrillator Efficacy and Revascularization May 2, 2006:1811–7.64) was very similar to that demonstrated among patients
n whom the ICD was implanted during the early post-CR
eriod in the MADIT-II study (1.19; p  0.76). Further
nalysis of the CABG-Patch trial, revealed that most of the
eaths (71%) in the study were nonarrhythmic in nature
15). In the current study, we have similarly shown that the
ode of death among patients enrolled during the early
ost-CR period was dominated by nonarrhythmic mortality
83%), whereas after this early time period the proportion of
eaths that were nonsudden in nature was reduced to 40%.
hus, it appears that both in MADIT-II study and the
ABG-Patch trial, the lack of defibrillator benefit when
mplanted in proximity to a CR procedure, was related to
he fact that most of deaths during this time period were
onarrhythmic in nature.
A previous analysis of the MADIT-II study (16) has
emonstrated that a significant decrease in the risk of SCD
ith ICD therapy was apparent within one year after
nrollment, whereas during this time period the rate of
on-SCD was significantly higher in the ICD group than in
he conventional therapy group, leading to an overall sig-
ificant survival benefit with ICD therapy only after the first
ear of the trial. In the present study we have consistently
hown that among patients enrolled more than six months
fter CR the rates of SCD were significantly lower in the
CD group than in the conventional therapy group within
oth one and two years after enrollment, leading to an
verall survival benefit with ICD therapy at two years in
atients who enrolled in the intermediate and late post-CR
Table 3. Two-Year Kaplan-Meier Cumulative
Cardiac Death in Each Subgroup of CR Type
ICD
Single PCI procedure (n  173)
All-cause mortality (%) 9
Sudden cardiac death (%) 0
Single CABG procedure (n  336)
All-cause mortality (%) 12
Sudden cardiac death (%) 8
1 CR procedure (n  442)
All-cause mortality (%) 8
Sudden cardiac death (%) 0
*p  0.10.
Abbreviations as in Table 1.
Table 4. Adjusted Mortality Risk by Elapsed T
Group
Variable <6 Months
7–6
HR
All-cause mortality 1 1.55 (0
Cardiac death 1 1.95 (0
SCD 1 5.96 (0
Non-SCD 1 0.66 (0
Adjusted for age 65 years, ejection fraction 25%, and
months. *p  0.05.
SCD  sudden cardiac death; other abbreviations as in Table 2eriods. In contrast, SCD rates in patients enrolled in the
arly post-CR period were similar in the two treatment arms
hroughout the study, leading to a neutral effect of ICD
herapy on all-cause mortality at two years in this subgroup
f patients.
tudy limitations. Coronary revascularization was not a
andomized event in the MADIT-II study; therefore, there
ere significant differences in the baseline characteristics
mong the post-CR subgroups. However, adjusting for
hose differences did not explain the differences in outcome
mong the post-CR subgroups.
Patients were excluded from enrollment in the
ADIT-II study if their most recent CR procedure was
erformed within three months before enrollment (only 12
atients were included within this time period owing to
uthorized protocol deviations). Therefore, the current re-
ults do not include sufficient data on the immediate
ost-CR period in which an even lower risk of SCD may
xist, corresponding to a further reduction in ICD benefit
uring this time period.
As compared with PCI, CABG provides a more com-
lete revascularization of the coronary arteries. Therefore,
he latter revascularization modality may afford better pro-
ection against arrhythmic mortality than the former. Data
n the completeness of revascularization were not available
n the current study. Thus, the effect of this important factor
as not analyzed. The consistent trends among patients
ho underwent PCI as an isolated procedure suggest that
abilities of All-Cause Mortality and Sudden
ime From CR
Time From CR
onths >6 Months
Conventional ICD Conventional
10 12 19
0 5 16*
10 16 29*
5 7 16*
5 12 17
0 3 9*
from Revascularization in the Conventional
nths
CI)
>60 Months
HR (95% CI) p for Trend
.82) 2.59 (1.08–6.25)* 0.01
.74) 3.26 (1.13–9.40)* 0.009
5.23) 6.78 (0.89–51.75) 0.07
.90) 1.24 (0.31–5.03) 0.56
ent with beta-blockers at baseline; reference group: 6Prob
by T
<6 Mime
0 Mo
(95%
.63–3
.66–5
.79–4
.15–2
treatm.
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May 2, 2006:1811–7 Defibrillator Efficacy and Revascularizationecent revascularization, limited to the target vessel, may
lso reduce the risk of arrhythmic mortality.
onclusions. We have shown that ICD therapy is associated
ith a significant survival benefit and reduction in SCD risk
fter CR. This life-saving benefit, however, is time dependent,
nd in the current analysis of the MADIT-II study, improved
urvival was apparent when the ICD was implanted more than
ix months after CR. Our findings suggest that the early
ost-CR period is dominated by nonarrhythmic mortality and
ay explain the lack of defibrillator benefit in the CABG-
atch trial. Further prospective studies are needed to delineate
he optimal timing of device implantation after CR. At
resent, the relatively low risk of arrhythmic mortality during
he early period after successful CR should be considered
hen planning ICD implantation for the primary preven-
ion of SCD in CHD patients with advanced left ventricular
ysfunction.
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eart Research Follow-Up Program, Box 653, University of
ochester Medical Center, Rochester, New York 14642. E-mail:
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